---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-038016"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2024-02-16T23:59:59+00:00"
generated_at: "2026-06-06T00:25:55.937748+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine prices $150.9M public offering of common stock and pre-funded warrants

## Summary
- Offering of 19,200,001 shares at $6.25/share plus pre-funded warrants for 3,200,005 shares.
- Net proceeds estimated at approximately $150.9M after underwriting discounts and expenses.
- Proceeds to fund R&D, clinical development, and general corporate purposes.
- Closing expected on or about February 20, 2024, subject to customary conditions.
- Underwriters granted 30-day option to purchase up to an additional 3,360,000 shares.

## SEC filing metadata
- accession: 0001193125-24-038016
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2024-02-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000119312524038016/0001193125-24-038016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000119312524038016/d721402d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-038016
- JSON: https://secwatch.observer/filing/0001193125-24-038016.json
- Plain text: https://secwatch.observer/filing/0001193125-24-038016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.